Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare disease therapies, has announced the grant of 45,292 restricted stock units (RSUs) to 29 newly hired non-executive officers. The grants were approved by the company's compensation committee and issued under the Ultragenyx Employment Inducement Plan on July 16, 2025.

The RSUs will vest over a four-year period, with 25% of the shares vesting annually on each grant date anniversary, contingent on continued employment.

News Market Reaction

+0.30%

1 alert

+0.30% News Effect

On the day this news was published, RARE gained 0.30%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What type of stock compensation did Ultragenyx (RARE) grant to new employees in July 2025?

Ultragenyx granted 45,292 restricted stock units (RSUs) to 29 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

What is the vesting schedule for Ultragenyx's July 2025 RSU grants?

The RSUs vest over four years, with 25% of the underlying shares vesting on each anniversary of the July 16, 2025 grant date.

How many new employees received RSUs from Ultragenyx in July 2025?

29 newly hired non-executive officers received restricted stock units from Ultragenyx.

Under which Nasdaq rule were Ultragenyx's July 2025 RSU grants made?

The RSU grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement material.